FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053436729> ?p ?o ?g. }

• W2053436729 endingPage "1014" @default.
• W2053436729 startingPage "1013" @default.
• W2053436729 abstract "Primary abnormalities of ciliary structure and function, termed primary ciliary dyskinesia (PCD), are often diagnosed late in adult and pediatric patients presenting with respiratory tract manifestations such as bronchiectasis, sinusitis, or with infertility. Accurate diagnosis requires the suspicion of clinicians, and referral to a specialist center with expertise in assessing ciliary ultrastructure by electron microscopy, and performing ciliary function studies. While no cure is available, once diagnosed, careful attention can be directed to minimizing morbidity through measures such as bronchial clearance and prompt treatment of infection.1Bush A Cole P Hariri M et al.Primary ciliary dyskinesia: diagnosis and standards of care.Eur Respir J. 1998; 12: 982-988Crossref PubMed Scopus (327) Google ScholarNitric oxide (NO) was discovered in the late 1980s to be an essential biological mediator in diverse species and systems.2Koshland Jr, DE The molecule of the year.Science. 1992; 258: 1861Crossref PubMed Scopus (417) Google Scholar This molecule is synthesized by a family of constitutive and inducible NO synthases. The nasal cavity and paranasal sinuses excrete concentrations of NO that can reach several parts per million, orders of magnitude higher than the lower airway.3Lundberg JO Farkas-Szallasi T Weitzberg E et al.High nitric oxide production in human paranasal sinuses.Nat Med. 1995; 1: 370-373Crossref PubMed Scopus (540) Google Scholar This exuberant synthesis of NO is sufficient for an important antibacterial and antiviral effect, perhaps ensuring sinus sterility in health. Of relevance here, NO also has been reported to modulate ciliary function. Inhalation via the nose, which conditions the inspirate with endogenous NO, has been reported to have discernible effects on ventilation-perfusion matching in the lung. This may represent an important physiologic mechanism controlling matching of ventilation to pulmonary blood flow, and supports parental advice to “breathe through your nose”! The measurement of nasal NO is described in an American Thoracic Society statement on exhaled and nasal NO measurement from 1999.4Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children-1999 This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999.Am J Respir Crit Care Med. 1999; 160: 2104-2117Crossref PubMed Scopus (936) Google ScholarIn this issue of CHEST (see page 1054), Corbelli et al measured nasal and exhaled NO in children with PCD proven by ciliary ultrastructure on electron microscopy and compared these to children with other lung conditions and healthy control subjects. Mean values for nasal NO in PCD were 13.7 parts per billion (ppb) [95% confidence limit, 6.8 to 27.8], compared to 132.7 ppb (95% confidence limit, 76.5 to 230.2) in non-PCD respiratory patients and 223.7 ppb (95% confidence limit, 175.5 to 285.2) for control subjects. Others have also reported similar findings as discussed by the authors. There are few tests that show such a profound contrast between health and disease. Exhaled NO did not differentiate between the three groups, although the numbers were smaller. A nasal NO < 105 ppb had a sensitivity of 94% and a specificity of 89% for proven PCD. A low nasal NO has also been reported in cystic fibrosis, non-PCD bronchiectasis, sinusitis, and panbronchiolitis, so a firm diagnosis requires examination of ciliary ultrastructure.Aside from a marker of PCD, NO production may be involved in ciliary motility. Thus, the administration of NO donors5Runer T Lindberg S Effects of nitric oxide on blood flow and mucociliary activity in the human nose.Ann Otol Rhinol Laryngol. 1998; 107: 40-46Crossref PubMed Scopus (48) Google Scholar and the precursor of NO, the amino acid L-arginine, have been reported to increase ciliary beat frequency, while inhibitors of NO synthase reduce ciliary beat frequency.6Kim JW Min YG Rhee CS et al.Regulation of mucociliary motility by nitric oxide and expression of nitric oxide synthase in the human sinus epithelial cells.Laryngoscope. 2001; 111: 246-250Crossref PubMed Scopus (41) Google Scholar Both inducible and constitutive NO synthase isoforms may be expressed in ciliated nasal epithelial cells.6Kim JW Min YG Rhee CS et al.Regulation of mucociliary motility by nitric oxide and expression of nitric oxide synthase in the human sinus epithelial cells.Laryngoscope. 2001; 111: 246-250Crossref PubMed Scopus (41) Google Scholar The low nasal NO could also be linked to a susceptibility to upper airway infection.So where do we go from here? Nasal NO should be available in specialist centers, and should be measured with simple and foolproof standardized techniques.4Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children-1999 This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999.Am J Respir Crit Care Med. 1999; 160: 2104-2117Crossref PubMed Scopus (936) Google Scholar7Silkoff PE Chatkin J Qian W et al.Nasal nitric oxide: a comparison of measurement techniques.Am J Rhinol. 1999; 13: 169-178Crossref PubMed Scopus (56) Google Scholar Larger studies should examine the utility for the diagnosis of PCD in patients with sinusitis and bronchiectasis by publishing ranges in health and disease. Careful controlled studies should examine whether therapeutic intervention to increase the levels of upper airway NO modulate ciliary function and if this improves clinical outcomes. Companies should endeavor to provide simple and cost-effective instruments to measure nasal NO and obtain regulatory medical device clearance with reimbursement codes. Awareness of PCD is being increased through the PCD Foundation (http://www.pcdfoundation.org). Registries of PCD patients will allow clinical trials to be performed and therapeutic agents to be validated for this rare but important set of conditions. Pharmaceutical companies may become interested if nasal NO augmentation, not only helps patients with PCD but also those with other abnormalities of ciliary function whether primary or secondary. Primary abnormalities of ciliary structure and function, termed primary ciliary dyskinesia (PCD), are often diagnosed late in adult and pediatric patients presenting with respiratory tract manifestations such as bronchiectasis, sinusitis, or with infertility. Accurate diagnosis requires the suspicion of clinicians, and referral to a specialist center with expertise in assessing ciliary ultrastructure by electron microscopy, and performing ciliary function studies. While no cure is available, once diagnosed, careful attention can be directed to minimizing morbidity through measures such as bronchial clearance and prompt treatment of infection.1Bush A Cole P Hariri M et al.Primary ciliary dyskinesia: diagnosis and standards of care.Eur Respir J. 1998; 12: 982-988Crossref PubMed Scopus (327) Google Scholar Nitric oxide (NO) was discovered in the late 1980s to be an essential biological mediator in diverse species and systems.2Koshland Jr, DE The molecule of the year.Science. 1992; 258: 1861Crossref PubMed Scopus (417) Google Scholar This molecule is synthesized by a family of constitutive and inducible NO synthases. The nasal cavity and paranasal sinuses excrete concentrations of NO that can reach several parts per million, orders of magnitude higher than the lower airway.3Lundberg JO Farkas-Szallasi T Weitzberg E et al.High nitric oxide production in human paranasal sinuses.Nat Med. 1995; 1: 370-373Crossref PubMed Scopus (540) Google Scholar This exuberant synthesis of NO is sufficient for an important antibacterial and antiviral effect, perhaps ensuring sinus sterility in health. Of relevance here, NO also has been reported to modulate ciliary function. Inhalation via the nose, which conditions the inspirate with endogenous NO, has been reported to have discernible effects on ventilation-perfusion matching in the lung. This may represent an important physiologic mechanism controlling matching of ventilation to pulmonary blood flow, and supports parental advice to “breathe through your nose”! The measurement of nasal NO is described in an American Thoracic Society statement on exhaled and nasal NO measurement from 1999.4Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children-1999 This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999.Am J Respir Crit Care Med. 1999; 160: 2104-2117Crossref PubMed Scopus (936) Google Scholar In this issue of CHEST (see page 1054), Corbelli et al measured nasal and exhaled NO in children with PCD proven by ciliary ultrastructure on electron microscopy and compared these to children with other lung conditions and healthy control subjects. Mean values for nasal NO in PCD were 13.7 parts per billion (ppb) [95% confidence limit, 6.8 to 27.8], compared to 132.7 ppb (95% confidence limit, 76.5 to 230.2) in non-PCD respiratory patients and 223.7 ppb (95% confidence limit, 175.5 to 285.2) for control subjects. Others have also reported similar findings as discussed by the authors. There are few tests that show such a profound contrast between health and disease. Exhaled NO did not differentiate between the three groups, although the numbers were smaller. A nasal NO < 105 ppb had a sensitivity of 94% and a specificity of 89% for proven PCD. A low nasal NO has also been reported in cystic fibrosis, non-PCD bronchiectasis, sinusitis, and panbronchiolitis, so a firm diagnosis requires examination of ciliary ultrastructure. Aside from a marker of PCD, NO production may be involved in ciliary motility. Thus, the administration of NO donors5Runer T Lindberg S Effects of nitric oxide on blood flow and mucociliary activity in the human nose.Ann Otol Rhinol Laryngol. 1998; 107: 40-46Crossref PubMed Scopus (48) Google Scholar and the precursor of NO, the amino acid L-arginine, have been reported to increase ciliary beat frequency, while inhibitors of NO synthase reduce ciliary beat frequency.6Kim JW Min YG Rhee CS et al.Regulation of mucociliary motility by nitric oxide and expression of nitric oxide synthase in the human sinus epithelial cells.Laryngoscope. 2001; 111: 246-250Crossref PubMed Scopus (41) Google Scholar Both inducible and constitutive NO synthase isoforms may be expressed in ciliated nasal epithelial cells.6Kim JW Min YG Rhee CS et al.Regulation of mucociliary motility by nitric oxide and expression of nitric oxide synthase in the human sinus epithelial cells.Laryngoscope. 2001; 111: 246-250Crossref PubMed Scopus (41) Google Scholar The low nasal NO could also be linked to a susceptibility to upper airway infection. So where do we go from here? Nasal NO should be available in specialist centers, and should be measured with simple and foolproof standardized techniques.4Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children-1999 This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999.Am J Respir Crit Care Med. 1999; 160: 2104-2117Crossref PubMed Scopus (936) Google Scholar7Silkoff PE Chatkin J Qian W et al.Nasal nitric oxide: a comparison of measurement techniques.Am J Rhinol. 1999; 13: 169-178Crossref PubMed Scopus (56) Google Scholar Larger studies should examine the utility for the diagnosis of PCD in patients with sinusitis and bronchiectasis by publishing ranges in health and disease. Careful controlled studies should examine whether therapeutic intervention to increase the levels of upper airway NO modulate ciliary function and if this improves clinical outcomes. Companies should endeavor to provide simple and cost-effective instruments to measure nasal NO and obtain regulatory medical device clearance with reimbursement codes. Awareness of PCD is being increased through the PCD Foundation (http://www.pcdfoundation.org). Registries of PCD patients will allow clinical trials to be performed and therapeutic agents to be validated for this rare but important set of conditions. Pharmaceutical companies may become interested if nasal NO augmentation, not only helps patients with PCD but also those with other abnormalities of ciliary function whether primary or secondary. Supplementary Material Download .doc (.04 MB) Help with doc files Supplementary appendix Download .doc (.04 MB) Help with doc files Supplementary appendix" @default.
• W2053436729 created "2016-06-24" @default.
• W2053436729 creator A5042743048 @default.
• W2053436729 date "2004-10-01" @default.
• W2053436729 modified "2023-09-26" @default.
• W2053436729 title "Nasal Nitric Oxide" @default.
• W2053436729 cites W1997081772 @default.
• W2053436729 cites W2017558835 @default.
• W2053436729 cites W2029864494 @default.
• W2053436729 cites W2068234811 @default.
• W2053436729 cites W2105375033 @default.
• W2053436729 cites W4211171942 @default.
• W2053436729 cites W4294617579 @default.
• W2053436729 doi "https://doi.org/10.1378/chest.126.4.1013" @default.
• W2053436729 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15486353" @default.
• W2053436729 hasPublicationYear "2004" @default.
• W2053436729 type Work @default.
• W2053436729 sameAs 2053436729 @default.
• W2053436729 citedByCount "6" @default.
• W2053436729 countsByYear W20534367292016 @default.
• W2053436729 crossrefType "journal-article" @default.
• W2053436729 hasAuthorship W2053436729A5042743048 @default.
• W2053436729 hasConcept C126322002 @default.
• W2053436729 hasConcept C519581460 @default.
• W2053436729 hasConcept C71924100 @default.
• W2053436729 hasConceptScore W2053436729C126322002 @default.
• W2053436729 hasConceptScore W2053436729C519581460 @default.
• W2053436729 hasConceptScore W2053436729C71924100 @default.
• W2053436729 hasIssue "4" @default.
• W2053436729 hasLocation W20534367291 @default.
• W2053436729 hasLocation W20534367292 @default.
• W2053436729 hasOpenAccess W2053436729 @default.
• W2053436729 hasPrimaryLocation W20534367291 @default.
• W2053436729 hasRelatedWork W1506200166 @default.
• W2053436729 hasRelatedWork W1995515455 @default.
• W2053436729 hasRelatedWork W2039318446 @default.
• W2053436729 hasRelatedWork W2048182022 @default.
• W2053436729 hasRelatedWork W2080531066 @default.
• W2053436729 hasRelatedWork W2604872355 @default.
• W2053436729 hasRelatedWork W2748952813 @default.
• W2053436729 hasRelatedWork W2899084033 @default.
• W2053436729 hasRelatedWork W3032375762 @default.
• W2053436729 hasRelatedWork W3108674512 @default.
• W2053436729 hasVolume "126" @default.
• W2053436729 isParatext "false" @default.
• W2053436729 isRetracted "false" @default.
• W2053436729 magId "2053436729" @default.
• W2053436729 workType "article" @default.